PCRX · Pacira BioSciences, Inc.
Market Cap
$1.05B
Shares
39.86M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$726.41M
+3.6%
FY2025
Net Income
$7.03M
+107.1%
FY2025
Gross Margin
79.39%
+3.7pp
FY2025
Operating Margin
2.64%
+13.1pp
FY2025
Diluted EPS
$0.16
+107.4%
FY2025
Operating Cash Flow
$151.99M
-19.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $746.16M | $726.41M | $700.97M | $674.98M | $666.82M | $541.53M | $429.65M | $421.03M | $337.28M | $286.63M | $276.37M | $249M | $197.67M | $85.55M | $39.08M | $15.69M | $14.56M | $15.01M | |
| $155.15M | $149.75M | $170.43M | $184.67M | $199.3M | $140.26M | $117.33M | $106.71M | $86.85M | $87.92M | $110.1M | $71.84M | $77.44M | $54.77M | $32.14M | $16.74M | $12.28M | $12.3M | |
| $591.01M | $576.66M | $530.54M | $490.31M | $467.53M | $401.28M | $312.32M | $314.31M | $250.43M | $198.72M | $166.27M | $177.16M | $120.23M | $30.78M | $6.95M | -$1.05M | $2.29M | $2.71M | |
| — | 79.39% | 75.69% | 72.64% | 70.11% | 74.1% | 72.69% | 74.65% | 74.25% | 69.33% | 60.16% | 71.15% | 60.82% | 35.98% | 17.77% | -6.69% | 15.7% | 18.03% | |
| $122.09M | $117.31M | $81.58M | $76.26M | $84.8M | $55.55M | $59.42M | $72.12M | $55.69M | $57.29M | $45.68M | $28.66M | $18.73M | $21.56M | $9.94M | $14.87M | $18.63M | $26.23M | |
| $379.16M | $368.76M | $294.1M | $269.44M | $254.52M | $199.35M | $193.52M | $200.78M | $177.27M | $161.49M | $152.61M | $139.04M | $106.66M | $62.51M | $46.31M | $20.16M | $6.37M | $5.02M | |
| $57.29M | $57.29M | $57.29M | $57.29M | $57.29M | $13.55M | $7.87M | $5.7M | $0 | $0 | $100K | $300K | $800K | $2.1M | $2.1M | $2.3M | $2.3M | — | |
| $85.16M | $91.02M | $78.79M | $75.57M | $91.5M | $28.55M | $19.91M | $19.58M | $13.17M | $13.83M | $12.92M | $11.48M | $10.04M | $5.75M | $5.65M | $4.31M | $4.07M | $4.15M | |
| — | $3.67M | $8.53M | $1.11M | $0 | $0 | -$38K | $847K | $1.56M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | $410.55M | $321.36M | $311.57M | $308.4M | $239.54M | $202.83M | $138.84M | $88.38M | $54.79M | $37.27M | $43.55M | |
| $726.29M | $707.22M | $774.34M | $587.3M | $606.8M | $451.61M | $383.3M | $410.55M | $321.36M | — | — | — | — | — | — | — | — | — | |
| $19.87M | $19.19M | -$73.37M | $87.68M | $60.02M | $89.92M | $46.35M | $10.48M | $15.92M | -$24.94M | -$32.02M | $9.46M | -$5.17M | -$53.29M | -$49.3M | -$39.1M | -$22.71M | -$28.55M | |
| — | 2.64% | -10.47% | 12.99% | 9% | 16.61% | 10.79% | 2.49% | 4.72% | -8.7% | -11.59% | 3.8% | -2.61% | -62.29% | -126.13% | -249.23% | -155.95% | -190.24% | |
| $105.03M | $110.21M | $5.41M | $163.25M | $151.53M | $118.47M | $66.26M | $30.06M | $29.08M | -$11.1M | -$19.11M | $20.93M | $4.87M | -$47.54M | -$43.65M | -$34.79M | -$18.64M | -$24.4M | |
| $15.49M | $17.45M | $16.57M | $20.31M | $39.98M | $31.75M | $25.67M | $23.63M | $21.95M | $18.05M | $7.06M | $7.73M | $8.28M | $7.25M | $1.81M | $4.78M | $3.96M | $1.72M | |
| $14.7M | $22.73M | $19.69M | $11.44M | $4.54M | $896K | $4.63M | $7.38M | $6.5M | $4.08M | $1.32M | $678K | $382K | $259K | $275K | $255K | $146K | $77K | |
| -$2.22M | -$2.32M | $10.27M | -$25.97M | -$46.72M | -$33.52M | -$26.26M | -$21.23M | -$16.34M | -$17.53M | -$5.82M | -$7.34M | -$8.38M | -$11.06M | -$2.98M | -$4.23M | -$4.44M | -$3.16M | |
| — | — | — | — | — | -$2.67M | $1.62M | -$4.32M | -$854K | $0 | $0 | — | — | — | — | — | — | — | |
| $17.65M | $16.87M | -$63.11M | $61.7M | $13.3M | $56.4M | $20.09M | -$10.75M | -$425K | -$42.47M | -$37.84M | $2.12M | -$13.54M | -$64.35M | -$52.28M | -$43.33M | — | — | |
| $3.01M | $9.84M | $36.45M | $19.75M | -$2.61M | $14.42M | -$125.43M | $268K | $46K | $140K | $105K | $264K | $173K | -$442K | $0 | $0 | — | — | |
| $14.64M | $7.03M | -$99.56M | $41.96M | $15.91M | $41.98M | $145.52M | -$11.02M | -$471K | -$42.61M | -$37.95M | $1.86M | -$13.72M | -$63.91M | -$52.28M | -$43.33M | -$27.15M | -$31.71M | |
| — | 0.97% | -14.2% | 6.22% | 2.39% | 7.75% | 33.87% | -2.62% | -0.14% | -14.87% | -13.73% | 0.75% | -6.94% | -74.7% | -133.77% | -276.17% | -186.44% | -211.3% | |
| $13.82M | $11.02M | -$99.46M | $42.58M | $15.36M | $41.83M | $145.52M | -$10.41M | -$297K | -$43.04M | -$37.93M | $1.88M | -$13.8M | -$63.93M | -$52.27M | -$43.31M | -$27.15M | — | |
| USD/shares | $0.36 | $0.16 | -$2.15 | $0.91 | $0.35 | $0.95 | $3.41 | -$0.27 | -$0.01 | -$1.07 | -$1.02 | $0.05 | -$0.39 | -$1.93 | — | — | — | — |
| USD/shares | $0.36 | $0.16 | -$2.15 | $0.89 | $0.34 | $0.92 | $3.33 | -$0.27 | -$0.01 | -$1.07 | -$1.02 | $0.04 | -$0.39 | -$1.93 | — | — | — | — |
| shares | — | 44.57M | 46.25M | 46.22M | 45.52M | 44.26M | 42.67M | 41.51M | 40.91M | 39.81M | 37.24M | 36.54M | 35.3M | 33.18M | 30.33M | 16.44M | 574K | 573.12K |
| shares | — | 45.04M | 46.25M | 51.98M | 46.54M | 45.63M | 43.68M | 41.51M | 40.91M | 39.81M | 37.24M | 41.3M | 35.3M | 33.18M | 30.33M | 16.44M | 574.07K | 573.12K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2025: $173.33M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
1.56×
Peer median 2.34×
EV/EBIT
58.50×
Peer median 17.65×
P/E (TTM)
—
Peer median 15.28×
Peer medians compare against the 47 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $726,411,000 | $700,966,000 | $674,978,000 | $666,823,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $722,854,000 | $697,186,000 | $672,245,000 | $664,150,000 | $538,966,000 | $426,614,000 | $418,926,000 | $332,427,000 |
| EXPAREL | $575,130,000 | $548,962,000 | $538,120,000 | $536,899,000 | $506,515,000 | $413,338,000 | $407,877,000 | — |
| ZILRETTA | $116,633,000 | $118,089,000 | $111,098,000 | $105,517,000 | $12,683,000 | $0 | $0 | — |
| Iovera | $24,178,000 | $22,813,000 | $19,685,000 | $15,258,000 | $16,162,000 | $8,817,000 | — | — |
| Bupivacaine Liposome Injectable Suspension | $6,913,000 | $7,322,000 | $3,342,000 | $6,476,000 | $3,606,000 | $4,459,000 | $3,153,000 | — |
| Royalty | $3,557,000 | $3,780,000 | $2,733,000 | $2,673,000 | $2,442,000 | $3,033,000 | $2,100,000 | $1,850,000 |
| Collaborative Licensing and Milestone Revenue | — | — | $0 | $0 | $125,000 | $0 | — | — |
| DepoCyte | — | — | — | — | — | — | $0 | $0 |
| EXPARE Lbupivacaineliposomeinjectablesuspension | — | — | — | — | — | $417,797,000 | $411,030,000 | $332,427,000 |
| Iovera Member | — | — | — | — | $16,162,000 | $8,817,000 | $7,896,000 | $0 |
Key facts
CIK
1396814
CUSIP
695127100
13F (30d)
161 filings
160 filers
Visit website
Investor relations